A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

Journal of Interferon and Cytokine Research

Volumn 24, Issue 1, 2004, Pages 37-41

  Sunkara, Usha ^a   Walczak, Janet R ^a   Summerson, Lori ^a   Rogers, Theresa ^a   Eisenberger, Mario ^a   Denmeade, Samuel ^a   Pili, Roberto ^a   Huff, Carol Ann ^a   Sinibaldi, Victoria ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DACARBAZINE; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 9144222966     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999004772719891     Document Type: Article

References (22)

1. JEMAL, A., MURRAY, T., SAMUELS, A., GHAFOOR, A., WARD, E., and THUN, M. (2003). Cancer statistics, 2003. CA 53, 5-26.
2. WHANG, Y.E., and GODLEY, P.A. (2003). Renal cell carcinoma. Curr. Opin. Oncol. 15, 213-216.
3. MOTZER, R.J., BANDER, N.H., and NANUS, D.M. (1996). Renal cell carcinoma. N. Engl. J. Med. 335, 865-875.
4. YAGODA, A. (1990). Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988. Prog. Clin. Biol. Res. 350, 227-241.
5. YAGODA, A., ABI-RACHED, B., and PETRYLAK, D. (1995). Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin. Oncol. 22, 42-65.
6. YANG, J.L., TOPALIAN, S.L., PARKINSON, D., SCHWARTZ-ENTRUBER, D.J., WEBER, J.S., ETTINGHAUSEN, S.E., WHITE, D.E., STEINBERG, S.M., COLE, D.J., KIM, H.I., LEVIN, R., GULARIA, A., MACFARLANE, M.P., WHITE, R.L., EINHORN, J.H., SEIPP, C.A., and ROSENBERG, S.A. (1994). Comparison of high dose and low dose intravenous interleukin-2 for therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol. 12, 1572-1576.
7. LAW, M.T., MOTZER, R.J., MAZUMADAR, M., SELL, S.W., WALTHER, P.J., O'CONNELL, M., KHAN, A., VLAMIS, V., VOGELSANG, N.J., and BAJORIN, D.F. (1995). Phase III randomized trial of interleukin-2 with or without lymphokine- activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824-832.
8. WIRTH, M.P. (1993). Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am. 20, 283-295.
9. MINASIAN, L.M., MOTZER, R.J., GLUCK, L., MAZUMDAR, M., VLAMIS, V., and KROWN, S.E. (1993). Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 with long-term follow-up. J. Clin. Oncol. 11, 1368-1375.
10. MOTZER, R.J., BACIK, J., MURPHY, B.A., RUSSO, P., and MAZUMDAR, M. (2002). Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carncinoma. J. Clin. Oncol. 20, 289-296.
11. RAYMOND, E., IZBICKA, E., SODA, H., GERSON, S.L., DUGAN, M., and VONHOFF, D.D. (1997). Activity of temozolomide against human tumor colony-forming units. Clin. Cancer Res. 3, 1769-1774.
12. NEWLANDS, E.S., O'REILLY, S.M., GLASER, M.G., BOWER, M., BROCK, C., BRAMPTON, M.H., COLQUHOUN, I., LEWIS, P., RICE-EDWARDS, J.M., ILLINGWORTH, R.D., and RICHARDS, P.G. (1996). The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer 32A, 2236-2241.
13. O'REILLY, S.M., NEWLANDS, E.S., GLASER, M.G., BRAMPTOM, M., RICE-EDWARDS, J.M., ILLINGWORTH, R.D., RICHARDS, P.G., KENNARD, C., COLQUHOUN, I.R., LEWIS, P., et al. (1993). Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur. J. Cancer 29A, 940-942.
14. BLEEHAN, N.M., NEWLANDS, E.S., LEE, S.M., THATCHER, N., SELBY, P., CALVERT, A.H., RUSTIN, G.J., BRAMPTON, M., and STEVENS, M.F. (1995). Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13, 910-913.
15. WOLL P.J., CROWTHER D., JOHNSON, P.W.M., SOUKOP, M., HARRIS, M., BRAMPTON, M.H., and NEWLANDS, E.S. (1995). Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br. J. Cancer 72, 183-184.
16. BRADA, M., JUDSON, I., MOORE, S., REIDENBERG, P., and STATKEVICH, P. (1999). Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer 81, 1022-1030.
17. NEWLANDS, E.S., BLACKLEDGE, G.R., SLACK, J.A., RUSTIN, G.J., SMITH, D.B., STUART, N.S., QUARTERMAN, C.P. HOFFMAN, R., STEVENS, M.F., BRAMPTON, M.H., and GIBSON, A.C. (1992). Phase I trial of temozolomide (CCRG 81045, M&B 39831: NSC 362856). Br. J. Cancer 65, 287-291.
18. STEVENS, M.F., HICKMAN, J.A., LANGDON, S.P., CHUBB, D., VICKERS, L., STONE, R., BAIG, G., GODDARD, C., GIBSON, N.W., SLACK, J.A., NEWTON, C., LUNT, E., FIZAMES, C., and LAVELLE, F. (1987). Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47, 5846-5852.
19. 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 5, 309-317.
20. MOTZER, R.J., SCHWARTZ, L., LAW, T.M., MURPHY, B.A., HOFFMAN, A.D., ALBINO, A.P., VLAMIS, V., and NANUS, D.M. (1995). Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J. Clin. Oncol. 13, 1950-1957.
21. AGARWALA, S.S., and KIRKWOOD, J.M. (2003). Temozolomide in combination with interferon alfa-2b in patients with metastatic melanoma: a phase 1 dose escalation study. Cancer 97, 121-127.
22. PARK, D.K., RYAN, C.W., DOLAN, M.E., VOGELZANG, N.J., and STADLER, W.M. (2003). A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother. Pharmacol. 50, 160-162.